<DOC>
	<DOCNO>NCT00212641</DOCNO>
	<brief_summary>The objective study characterize pharmacodynamic profile , safety tolerability ONO-5129 patient Type 2 Diabetes mellitus</brief_summary>
	<brief_title>A Phase II Study Evaluate Effects Oral ONO-5129 Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>1 . Type 2 Diabetes Mellitus 2 . FBG level &gt; 140 mg/dL &lt; 270 mg/dL 3 . Fasting TG level &lt; 500 mg/dL 4 . BMI 22 40 kg/m2 , inclusive 5 . Other Inclusion criterion specify study protocol 1 . Previous participation ONO5129 protocol 2 . Previous treatment TZD agent current antidiabetic 3 . History myocardial infarction , coronary artery surgery , atrial/ventricular tachycardia , atrial/ventricular fibrillation past six month 4 . Presence functional limitation due cardiovascular disease accordance New York Heart Association Classification System Class III ( moderate ) IV ( severe ) 5 . Other exclusion criterion specify study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>